Algernon partners with Yale University for phase II DMT study

Mugglehead
By Rowan DunneOct 24, 2022, 9:57 pm214 pts
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) has entered a clinical trials agreement with one of the most prominent universities in the world to study a powerful psychedelic compound. On Monday, the drug development company announced a new partnership with Yale University to…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Knocking Over the Glasses 69

Texas Hemp Advocates Nearing 150,000 Signatures Urging Gov. Abbott to Veto SB 3 69

Ohio GOP Lawmakers Can’t Agree On How To Amend Marijuana Law, Causing Planned Vote To Be Canceled 64

Nevada opens foster parenting to those with cannabis records 39

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.